Xenon Pharmaceuticals Inc.
XENE
$42.88
-$0.63-1.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -43.56% | -39.77% | -33.32% | -28.48% | -21.90% |
| Total Depreciation and Amortization | 102.77% | 11.11% | 13.39% | 22.61% | -60.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.40% | 52.49% | 105.28% | 95.57% | 192.75% |
| Change in Net Operating Assets | -202.20% | -3,027.55% | 45.06% | -18.49% | -67.22% |
| Cash from Operations | -55.18% | -42.98% | -20.85% | -20.04% | -9.41% |
| Capital Expenditure | 46.67% | 47.21% | 18.59% | 45.26% | 67.49% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 249.23% | 285.88% | 224.31% | 258.91% | -240.84% |
| Cash from Investing | 246.46% | 279.94% | 220.63% | 248.13% | -251.92% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -95.15% | -96.22% | -96.24% | -96.57% | 997.83% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -95.15% | -96.22% | -96.24% | -96.57% | 997.83% |
| Foreign Exchange rate Adjustments | -121.19% | 12.44% | -2,638.00% | -544.68% | -128.50% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 241.33% | -101.87% | 644.09% | -106.49% | -205.31% |